Oslo, Norway, October 28, 2022 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced the presentation of a
poster at the European Society of Gynaecological Oncology's 23rd Annual Meeting,
being held in Berlin, October 27-30. The presentations will include results from
a pre-planned interim analysis of the VB C-02 trial with VB10.16, Nykode's
wholly owned therapeutic DNA vaccine specifically targeting antigen presenting
cells, in combination with atezolizumab in patients with advanced HPV16-positive
cervical cancer.

The new data further supports the use of specific blood based biomarkers as
prognostic and predictive factors of treatment outcome.

Michael Engsig, Nykode's Chief Executive Officer, stated: "It is a great
opportunity to present the VB C-02 interim data, including data that have not
been released before, to the scientific community at ESGO. We look forward to
continue updating the scientific community as we dive deeper into the interim
data of VB C-02 to further our understanding of how VB10.16 works to the benefit
of patients and how biomarkers can be used to predict clinical outcome."

Poster accepted for presentation at ESGO 2022
Abstract ID 447